About gni ltd - GNIIF
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Japan and China. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales. The China segment covers the integrated bio-pharma operations consisting of validation, preclinical trials, formulation, phase I to III clinical trials, manufacturing and sales. The company was founded on November 20, 2001 and is headquartered in Tokyo, Japan.
GNIIF At a Glance
GNI Group Ltd.
Nihonbashi-Honcho YS Building, 3/F
Tokyo, Tokyo 103-0023
| Phone | N/A | Revenue | 179.41M | |
| Industry | Biotechnology | Net Income | -28,369,075.83 | |
| Sector | Health Technology | 2025 Sales Growth | 15.113% | |
| Fiscal Year-end | 12 / 2026 | Employees | 990 | |
| View SEC Filings |
GNIIF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.50 |
| Price to Book Ratio | 2.668 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -104.551 |
| Enterprise Value to Sales | 4.507 |
| Total Debt to Enterprise Value | 0.175 |
GNIIF Efficiency
| Revenue/Employee | 181,224.592 |
| Income Per Employee | -28,655.632 |
| Receivables Turnover | 3.465 |
| Total Asset Turnover | 0.362 |
GNIIF Liquidity
| Current Ratio | 4.246 |
| Quick Ratio | 3.855 |
| Cash Ratio | 2.451 |
GNIIF Profitability
| Gross Margin | 74.49 |
| Operating Margin | -8.547 |
| Pretax Margin | -17.299 |
| Net Margin | -15.812 |
| Return on Assets | -5.718 |
| Return on Equity | -10.261 |
| Return on Total Capital | -6.133 |
| Return on Invested Capital | -7.181 |
GNIIF Capital Structure
| Total Debt to Total Equity | 44.098 |
| Total Debt to Total Capital | 30.603 |
| Total Debt to Total Assets | 26.483 |
| Long-Term Debt to Equity | 39.422 |
| Long-Term Debt to Total Capital | 27.358 |